In an interview, Takeda Pharmaceutical Company (OTCPK:TKPYY +1.6%) CFO Costa Saroukos said that the company could sell up to $10B in non-core assets to help finance its $62B...
Investors in Shire plc (NASDAQ:SHPG) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 7, 2018 $150.00 Put had some of...
Shire plc (NASDAQ:SHPG) announced that the European Commission (EC) has granted marketing approval to Takhzyro (lanadelumab) subcutaneous injection, for routine prevention of...
Shire Plc (NASDAQ:SHPG) announced that the European Union antitrust regulators have granted a phase I conditional approval to Takeda Pharmaceutical Co. Ltd.'s $62-billion bid to...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Strong Sell||Strong Sell||Sell||Strong Sell||Buy|
|Technical Indicators||Strong Sell||Sell||Strong Sell||Strong Sell||Strong Buy|
|Summary||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Outside Up||1H||1||Dec 10, 2018 12:00PM|
|Bullish Engulfing||1H||2||Dec 10, 2018 11:00AM|
|Engulfing Bearish||1W||4||Nov 11, 2018|
|Three Inside Up||30||4||Dec 10, 2018 11:30AM|
|Advance Block Bearish||1M||7||May 18|
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience Ophthalmology, Hematology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).Read More
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$2000||Start Trading|
|U.S. Commodity Futures Trading Commission (United States)||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.